A Double-Blind, Randomized, Placebo-Controlled Clinical Trial on Benfotiamine Treatment in Patients With Diabetic Nephropathy

OBJECTIVE: To investigate the effect of benfotiamine on urinary albumin excretion (UAE) and the tubular damage marker kidney injury molecule-1 (KIM-1) in patients with type 2 diabetes and nephropathy. RESEARCH DESIGN AND METHODS: Patients with type 2 diabetes and UAE equivalent to 15–300 mg/24 h, de...

Descripción completa

Detalles Bibliográficos
Autores principales: Alkhalaf, Alaa, Klooster, Astrid, van Oeveren, Willem, Achenbach, Ulrike, Kleefstra, Nanne, Slingerland, Robbert J., Mijnhout, G. Sophie, Bilo, Henk J.G., Gans, Reinold O.B., Navis, Gerjan J., Bakker, Stephan J.L.
Formato: Texto
Lenguaje:English
Publicado: American Diabetes Association 2010
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2890365/
https://www.ncbi.nlm.nih.gov/pubmed/20413516
http://dx.doi.org/10.2337/dc09-2241
Descripción
Sumario:OBJECTIVE: To investigate the effect of benfotiamine on urinary albumin excretion (UAE) and the tubular damage marker kidney injury molecule-1 (KIM-1) in patients with type 2 diabetes and nephropathy. RESEARCH DESIGN AND METHODS: Patients with type 2 diabetes and UAE equivalent to 15–300 mg/24 h, despite ACE inhibitors (ACE-Is) or angiotensin receptor blockers (ARBs), were randomly assigned to 12 weeks of benfotiamine (900 mg/day) (n = 39) or placebo (n = 43). RESULTS: Compared with placebo, benfotiamine treatment resulted in significant improvement of thiamine status (P < 0.001). Benfotiamine treatment did not significantly decrease 24-h UAE or 24-h KIM-1 excretion. CONCLUSIONS: In patients with type 2 diabetes and nephropathy, high-dose benfotiamine treatment for 12 weeks in addition to ACE-Is or ARBs did not reduce UAE or KIM-1 excretion, despite improvement of thiamine status.

Ejemplares similares